These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 29886050)

  • 1. Molecular epidemiology of Clostridioides (Clostridium) difficile strains recovered from clinical trials in the US, Canada and Europe from 2006-2009 to 2012-2015.
    Cheknis A; Johnson S; Chesnel L; Petrella L; Sambol S; Dale SE; Nary J; Sears P; Citron DM; Goldstein EJC; Gerding DN
    Anaerobe; 2018 Oct; 53():38-42. PubMed ID: 29886050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Clostridioides difficile isolates recovered from two Phase 3 surotomycin treatment trials by restriction endonuclease analysis, PCR ribotyping and antimicrobial susceptibilities.
    Cheknis A; Devaris D; Chesnel L; Dale SE; Nary J; Sambol SP; Citron DM; Goering RV; Johnson S
    J Antimicrob Chemother; 2020 Nov; 75(11):3120-3125. PubMed ID: 32747931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in molecular epidemiology and antimicrobial resistance profiles of Clostridioides (Clostridium) difficile strains in the United States between 2011 and 2017.
    Tickler IA; Obradovich AE; Goering RV; Fang FC; Tenover FC;
    Anaerobe; 2019 Dec; 60():102050. PubMed ID: 31173889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nationwide study of molecular epidemiology and antimicrobial susceptibility of Clostridioides difficile in South Korea.
    Byun JH; Kim H; Kim JL; Kim D; Jeong SH; Shin JH; Kim YA; Shin JH; Shin KS; Uh Y
    Anaerobe; 2019 Dec; 60():102106. PubMed ID: 31655214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011-2014.
    Freeman J; Vernon J; Pilling S; Morris K; Nicholson S; Shearman S; Longshaw C; Wilcox MH;
    Clin Microbiol Infect; 2018 Jul; 24(7):724-731. PubMed ID: 29066403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization, toxin detection and resistance testing of human clinical Clostridium difficile isolates from Lebanon.
    Berger FK; Rasheed SS; Araj GF; Mahfouz R; Rimmani HH; Karaoui WR; Sharara AI; Dbaibo G; Becker SL; von Müller L; Bischoff M; Matar GM; Gärtner B
    Int J Med Microbiol; 2018 Apr; 308(3):358-363. PubMed ID: 29478838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clostridioides (Clostridium) difficile infection burden in Japan: A multicenter prospective study.
    Kato H; Senoh M; Honda H; Fukuda T; Tagashira Y; Horiuchi H; Chiba H; Suzuki D; Hosokawa N; Kitazono H; Norisue Y; Kume H; Mori N; Morikawa H; Kashiwagura S; Higuchi A; Kato H; Nakamura M; Ishiguro S; Morita S; Ishikawa H; Watanabe T; Kojima K; Yokomaku I; Bando T; Toimoto K; Moriya K; Kasahara K; Kitada S; Ogawa J; Saito H; Tominaga H; Shimizu Y; Masumoto F; Tadera K; Yoshida J; Kikuchi T; Yoshikawa I; Watanabe T; Honda M; Yokote K; Toyokawa T; Miyazato H; Nakama M; Mahe C; Reske K; Olsen MA; Dubberke ER
    Anaerobe; 2019 Dec; 60():102011. PubMed ID: 30872073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients.
    Kociolek LK; Gerding DN; Osmolski JR; Patel SJ; Snydman DR; McDermott LA; Hecht DW
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4896-900. PubMed ID: 27270275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-genome analysis reveals the evolution and transmission of an MDR DH/NAP11/106 Clostridium difficile clone in a paediatric hospital.
    Kociolek LK; Ozer EA; Gerding DN; Hecht DW; Patel SJ; Hauser AR
    J Antimicrob Chemother; 2018 May; 73(5):1222-1229. PubMed ID: 29342270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative genomics analysis of Clostridium difficile epidemic strain DH/NAP11/106.
    Kociolek LK; Gerding DN; Hecht DW; Ozer EA
    Microbes Infect; 2018 Apr; 20(4):245-253. PubMed ID: 29391259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality assurance for genotyping and resistance testing of Clostridium (Clostridioides) difficile isolates - Experiences from the first inter-laboratory ring trial in four German speaking countries.
    Berger FK; Mellmann A; von Müller L; Bischoff M; Gärtner BC;
    Anaerobe; 2020 Feb; 61():102093. PubMed ID: 31494260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016.
    Thorpe CM; McDermott LA; Tran MK; Chang J; Jenkins SG; Goldstein EJC; Patel R; Forbes BA; Johnson S; Gerding DN; Snydman DR
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31085514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of strain typing results for Clostridium difficile isolates from North America.
    Tenover FC; Akerlund T; Gerding DN; Goering RV; Boström T; Jonsson AM; Wong E; Wortman AT; Persing DH
    J Clin Microbiol; 2011 May; 49(5):1831-7. PubMed ID: 21389155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The recognition and characterisation of Finnish Clostridium difficile isolates resembling PCR-ribotype 027.
    Krutova M; Nyc O; Matejkova J; Kuijper EJ; Jalava J; Mentula S
    J Microbiol Immunol Infect; 2018 Jun; 51(3):344-351. PubMed ID: 28583353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular epidemiology of Clostridioides (previously Clostridium) difficile isolates from a university hospital in Minas Gerais, Brazil.
    Diniz AN; de Oliveira Júnior CA; Vilela EG; Figueiredo HCP; Rupnik M; Wilcox MH; Fawley WN; Blanc DS; Faria Lobato FC; Silva ROS
    Anaerobe; 2019 Apr; 56():34-39. PubMed ID: 30703440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in Clostridium (Clostridioides) difficile PCR-Ribotype Distribution and Antimicrobial Resistance in a German Tertiary Care Hospital Over the Last 10 Years.
    Piepenbrock E; Stelzer Y; Berger F; Jazmati N
    Curr Microbiol; 2019 Apr; 76(4):520-526. PubMed ID: 30805700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular epidemiology and resistance profiles of Clostridium difficile in a tertiary care hospital in Spain.
    Weber I; Riera E; Déniz C; Pérez JL; Oliver A; Mena A
    Int J Med Microbiol; 2013 Apr; 303(3):128-33. PubMed ID: 23523477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for C. difficile infections: 2005-2007.
    Cheknis AK; Sambol SP; Davidson DM; Nagaro KJ; Mancini MC; Hidalgo-Arroyo GA; Brazier JS; Johnson S; Gerding DN
    Anaerobe; 2009 Dec; 15(6):230-3. PubMed ID: 19737618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug-resistant North American pulsotype 2 Clostridium difficile was the predominant toxigenic hospital-acquired strain in the province of Manitoba, Canada, in 2006-2007.
    Karlowsky JA; Zhanel GG; Hammond GW; Rubinstein E; Wylie J; Du T; Mulvey MR; Alfa MJ
    J Med Microbiol; 2012 May; 61(Pt 5):693-700. PubMed ID: 22301615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotic resistance of clinical isolates of Clostridioides difficile in China and its association with geographical regions and patient age.
    Li H; Li WG; Zhang WZ; Yu SB; Liu ZJ; Zhang X; Wu Y; Lu JX
    Anaerobe; 2019 Dec; 60():102094. PubMed ID: 31499177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.